THE IMPACT OF BODY MASS INDEX ON NT- proBNP VALUES IN HEART FAILURE PATIENTS

Mạnh Tuấn Hà1,, Ánh Dương Đỗ2
1 University of Medicine and Pharmacy at Ho Chi Minh City
2 City University of Medicine and Pharmacy Hospital. Ho Chi Minh

Main Article Content

Abstract

Background: There is a relationship between N- terminal pro B-type natriuretic peptide (NT- proBNP) leVels and body mass index (BMI). The study aimed to explore                the        impact                of         BMI       on         NT-proBNP concentrations and to examine whether other factors independent of or combined with BMI affect NT- proBNP            Values               in          patients             with                  heart                 failure. Methods: A cross-sectional study was conducted in patients with heart failure class II- IV New York Heart Association   (NYHA).                Results:   A   total      of 293 participants were recruited. The mean age was 68.9±13.2 years, males accounted for 46.4% of the total cohort, the mean BMI was 23.1±4.0 kg/m2, and the median NT- proBNP leVel was 3,776 (1,672-8,806) pg/ml. There was an inVerse relationship between BMI and log NT-proBNP (r=-0.29; p<0.001, Spearman correlation). The independent inVerse determinants of NT-proBNP other than BMI were male sex and eGFR, while the Variables directly correlated to NT-proBNP were LVEF ≤40% and NYHA class III-IV heart failure. Each standard deViation increase in BMI (4 kg/m2) was associated with a 7% decrease in NT-proBNP Values in the total cohort. Conclusions: There is an inVerse association between BMI and NT-proBNP leVels. Other Variables independent of or combined with BMI affect NT-proBNP Values, but BMI has a significant impact on the NT-proBNP Values in the diagnosis of heart failure. Keywords: body mass index (BMI); heart failure;

Article Details

References

1. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50(25): 2357-68.
2. McDonagh TA, Metra M, Adamo M, et al.
2021 ESC Guidelines for the diagnosis and



treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599-726.
3. Heil B, Tang WH. Biomarkers: Their potential in the diagnosis and treatment of heart failure. CleVe Clin J Med 2015; 82(12 Suppl 2): S28-35.
4. Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR, et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 2007; 167(4): 400-7.

5. Kim HL, Kim MA, Oh S, et al. The Impact of Body Mass Index on the Prognostic Value of N- Terminal proB-Type Natriuretic Peptide in Patients with Heart Failure: an Analysis from the Korean Heart Failure (KorHF) Registry. Int J Heart Fail 2020; 2(1): 45-54.
6. Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol 2014; 176(3): 611-7.